Pulmonary Hypertension Perioperative Management

Similar documents
Nothing to Disclose. Severe Pulmonary Hypertension

Pulmonary Hypertension in 2012

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program

Pulmonary Hypertension: Another Use for Viagra

Teaching Round Claudio Sartori

Pulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes

Pharmacy Management Drug Policy

Pulmonary Hypertension: Clinical Features & Recent Advances

Pulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine

PVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program

Pediatric Pulmonary Hypertension: Inside Out

Pulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH

PULMONARY HYPERTENSION

Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college

Update in Pulmonary Arterial Hypertension

Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?

22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment

PVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program

Recent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine

SA XXXX Special Authority for Subsidy

Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06

PREOPERATIVE CARDIOPULMONARY ASSESSMENT FOR LIVER TRANSPLANTATION James Y. Findlay Mayo Clinic College of Medicine, Rochester, MN, USA.

5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none

ADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION

Neonatal and Pediatric Pulmonary Vascular Disease

PULMONARY HYPERTENSION & THALASSAEMIA

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY

The Hemodynamics of PH Interpreting the numbers

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

Advances in Pharmacotherapy of PAH

Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007

The Case of Marco Nazzareno Galiè, M.D.

Approach to Pulmonary Hypertension in the Hospital

Pulmonary Hypertension Due to Left Heart Disease

Referral Forms for TYVASO and REMODULIN

Recruitment and Consenting

Pharmacy Management Drug Policy

Pulmonary Arterial Hypertension - Overview

Pulmonary Arterial Hypertension - Overview

Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension

Pulmonary Vasodilator Treatments in the ICU Setting

ADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Valutazione del neonato con sospetta ipertensione polmonare

REVATIO (sildenafil)

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Case Presentation: Anesthetic Management For POEM Procedure in a Patient with Severe Pulmonary Hypertension CHUCK STRAUBHAAR BSN, SRNA

Navigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines

Managing Multiple Oral Medications

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Disclosures. ICU Management of Advanced Lung Disease 5/9/2015. No Disclosures. All pictures from commercial sources

Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)

Disclosures. Objectives 6/16/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension

National Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Pulmonary Hypertension Drugs

Paediatric PAH in the current era

Pulmonary Hypertension: Definition and Unmet Needs

PDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder

Pulmonary Heart Disease: Evaluation and Management

Disclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension

Pulmonary hypertension on. Simon MacDonald BSc(Hons) BMBCh DPhil FRCP Consultant Cardiologist in Adult Congenital Heart Disease

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)

ino in neonates with cardiac disorders

Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease

It has been more than a decade since

Pulmonary Arterial Hypertension (PAH) Treatments

Chronic Thromboembolic Pulmonary Hypertention CTEPH

Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension

PULMONARY ARTERIAL HYPERTENSION AGENTS

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced

THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

Sildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016

Pulmonary hypertension and right ventricular failure

Index. Note: Page numbers of article titles are in boldface type

Corporate Medical Policy

Review Article Diagnosis and Management of Pulmonary Arterial Hypertension

Pulmonary Hypertension: Classification

ACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO

DECLARATION OF CONFLICT OF INTEREST

Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών

A Best Practices Approach to Treating Pulmonary Hypertension for the ED and Acute Care Provider. Disclosures

4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology

PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER

Chronic Pulmonary Complications HEMO 2016 Florianopolis, November 12, 2016

2/4/2011. Nathan Kerner, M.D.

The Case of Lucia Nazzareno Galiè, M.D.

Pharmacy Management Drug Policy

PULMONARY HYPERTENSION

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:

Untreated idiopathic pulmonary arterial hypertension

Pulmonary Hypertension: Evolution and

Transcription:

Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida

Introduction Definition of Pulmonary Hypertension Increased Mean Pulmonary Arterial Pressure mpap > 25mmHg at Rest Normal: 14 (11-17) mmhg mpap > 30 mmhg Dropped from Definition Found in Many Normal Patients McLaughlin et al., Circulation 2009; 119:2250 Kovace et al., Eur Respir J 2009; 34:888

Introduction (cont.) Types of Pulmonary Hypertension Pulmonary Arterial Hypertension With Left-Sided Heart Disease With Lung Disease/Hypoxemia Due to Chronic Thrombosis/Emboli Miscellaneous Sarcoidosis, Histiocystosis X, Lymphangiomatosis, Compression of Pulmonary Vessels (Adenopathy, Tumor, Fibrosing Mediatinitis) Simonneau et al., J Am Coll Cardiol 2004; 43(12, suppl S):5S

Pulmonary Arterial Hypertension Etiology Idiopathic Familial Associated with Diseases/Conditions Collagen Vascular Disease, Congenital Shunts, Portal Hypertension, HIV, Drugs/Toxins, Miscellany Venous or Capillary Disease Persistent PAH of the Newborn Simonneau et al., J Am Coll Cardiol 2004; 43(12, suppl S):5S

Pulmonary Arterial Hypertension (cont.) Lung Diseases COPD Interstitial Lung Disease Sleep-Disordered Breathing/Obstructive Sleep Apnea Alveolar Hypoventilation Long-Term Exposure to High Altitude Developmental Abnormalities Simonneau et al., J Am Coll Cardiol 2004; 43(12, suppl S):5S

Natural History Median Life Expectancy 2.8 years Prevention Screening of High Risk Patients Family History Congenital Heart Disease Connective Tissue Disease Symptoms of PAH

Pulmonary Hypertension Therapeutic Options Reversal of Hypoxemia Management of Left Heart Failure Vasodilators Calcium Channel Blockers Prostacyclin Analogues Endothelin Receptor Antagonists PDE-V Inhibitors

Pulmonary Hypertension (cont.) Therapeutic Options Calcium Channel Blockers Nifedipine, Diltiazem, Amlodipine Minimally Effective in Treating PAH Prostacyclin Analogues Epoprostenol (Intravenous) Treprostinil (Oral and Intravenous) Iloprost (Inhaled) Endothelin Receptor Antagonists Bosentan (Oral) PDE-V Inhibitors Sildanefil

Perioperative Risk Marked Increase in Risk 29% Complication Rate 4/28 Mortality Mild to Moderate Pulmonary Hypertension Emergency Procedures, Major Surgery, Long Operative Times Increase Risk Price et al., Eur Respir J 2010;35:1294

PAH Perioperative Management Assessing Risk Contraindication to Liver Transplantation Thoracic Surgery Changes in Lung Volume, Intrathoracic Pressure, Oxgenation Acute Changes in PVR and RV Function Laparoscopy Decrease Preload, Increased Afterload Rapid Intraoperative Blood Loss Peripartum Therapy Decreases Mortality (38% to 25%) Ross Curr Opin Anesthesiol 2010; 23:25 Pedoto Curr Opin Anesthesiol 2010; 22:44 Bedard Eur Heart J 2009; 30:256

Pulmonary Hypertension (cont.) Effect on Outcomes 145 Patients Retrospective Analysis Non-Cardiac Surgery General Anesthetic 42% Short-Term Morbid Events Respiratory Failure (28%) Cardiac Dysrhythmia (12%) Congestive Heart Failure (11%) 7% (n=10) Death Within 30 d Respiratory Failure (60%), RV Failure (50%) Ramakrishna et al, J Am Coll Cardiol 2005;45:1691

Pulmonary Hypertension (cont.) Effect on Outcomes Thoracic Surgical Patients 61.5% Morbidity Orthopedic Surgical Patients 48% Morbidity Gynecologic/Urologic/Plastic/Breast Surgical Patients 16.7% Morbidity Ramakrishna et al, J Am Coll Cardiol 2005;45:1691

Pulmonary Hypertension (cont.) Effect on Outcomes 173 Patients; 96 PAH, 77 Control Non-Cardiac Surgery PAH Significant Risk for Congestive Heart Failure Sepsis Respiratory Failure Kaw et al., Respir Med 2011;105:619

Pulmonary Hypertension (cont.) Effect on Outcomes RVSP/SBP Ratio >0.66 Associated with Short-Term Morbidity CHF Most Frequent Post-Operative Event Patients More Likely to Require Post- Operative ICU Care Patients More Likely Readmitted to Hospital Within 30 d Kaw et al., Respir Med 2011;105:619

Pulmonary Hypertension (cont.) Preoperative Assessment Evaluation of Symptoms Functional Capacity ECG, Chest Radiograph, Echocardiogram Arterial Blood Gas

Pulmonary Hypertension (cont.) Preoperative Assessment Evaluation for RV Dysfunction Right Heart Catheterization Re-Evaluation of Surgery Aggressive Intervention COPD Patients Supplemental Oxygen Bronchodilators Antibiotics Steroids Cardiac (LV Dysfunction) Patients Inotropes Vasodilators

Perioperative Management Anesthetic Technique Maintain Preload and SVR Maximize Cardiac Function Maximize Right Heart Perfusion Systolic to RV Systolic Gradient Prevent Increases in PVR Hypoxia, Hypercarbia, Acidosis, Agitation, Pain, Hypothermia Aggressive Treatment of Hypotension Vasoconstrictors Inotropic Support Modulation of PVR in RV Failure Inhaled Prostaglandins (Iloprost)

Perioperative Management (cont.) Anesthetic Monitoring Intermediate to High Risk Procedures Thoracotomy/Thoracoscopy Prolonged Laparoscopy Open Intra-Abdominal Procedures Invasive Monitoring Pulmonary Artery Catheter Transesophageal Echocardiography Intensive Therapy Inhaled Iloprost Inhaled Nitric Oxide Intravenous Prostacyclin Inotropic Therapy to Maintain RV Perfusion/Cardiac Function